Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CFRX NASDAQ:EQ NASDAQ:LPTX NASDAQ:ORMP NASDAQ:PRPH On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCFRXContraFect$0.05$0.05$0.04▼$13.02$535K0.291.39 million shs910,216 shsEQEquillium$0.36+3.1%$0.36$0.27▼$1.50$12.82M1.86464,592 shs230,320 shsLPTXLeap Therapeutics$0.33-7.7%$0.36$0.22▼$4.79$13.59M-0.281.09 million shs286,501 shsORMPOramed Pharmaceuticals$2.15+1.4%$2.19$1.82▼$3.09$87.83M1.59141,093 shs14,249 shsPRPHProPhase Labs$0.43-0.9%$0.36$0.22▼$3.64$17.70M-0.413.13 million shs310,786 shsInvesting Strategies To Help Grow Your Retirement IncomeNeed to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCFRXContraFect0.00%0.00%0.00%0.00%0.00%EQEquillium+3.29%+6.48%-0.68%-27.31%-52.43%LPTXLeap Therapeutics+4.26%+23.33%-14.96%+9.63%-81.88%ORMPOramed Pharmaceuticals-2.30%-2.93%-4.93%+0.47%-14.86%PRPHProPhase Labs+1.34%+5.86%+22.84%+39.32%-87.61%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCFRXContraFectN/AN/AN/AN/AN/AN/AN/AN/AEQEquillium1.8721 of 5 stars3.22.00.00.01.11.70.6LPTXLeap Therapeutics1.5975 of 5 stars3.02.00.00.01.10.01.3ORMPOramed Pharmaceuticals0.2984 of 5 stars0.03.00.00.00.00.80.6PRPHProPhase Labs0.4938 of 5 stars0.05.00.00.00.00.00.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCFRXContraFect 0.00N/AN/AN/AEQEquillium 2.33Hold$3.00749.86% UpsideLPTXLeap Therapeutics 2.00Hold$3.38875.43% UpsideORMPOramed Pharmaceuticals 2.00HoldN/AN/APRPHProPhase Labs 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownCompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCFRXContraFectN/AN/AN/AN/A($19.92) per shareN/AEQEquillium$41.10M0.31N/AN/A$0.54 per share0.65LPTXLeap TherapeuticsN/AN/AN/AN/A$0.91 per shareN/AORMPOramed Pharmaceuticals$1.34M65.39N/AN/A$3.61 per share0.59PRPHProPhase Labs$5.85M3.05N/AN/A$0.25 per share1.72Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCFRXContraFect-$65.15M-$19.27N/AN/AN/AN/AN/A-138.70%N/AEQEquillium-$8.07M-$0.39N/AN/AN/A-19.62%-74.34%-46.75%8/6/2025 (Estimated)LPTXLeap Therapeutics-$67.56M-$1.70N/AN/AN/AN/A-162.15%-120.05%8/11/2025 (Estimated)ORMPOramed Pharmaceuticals-$19.06M-$0.44N/AN/AN/AN/A-11.34%-10.73%8/13/2025 (Estimated)PRPHProPhase Labs-$53.36M-$1.26N/AN/AN/AN/A-184.38%-64.59%8/13/2025 (Estimated)Latest EQ, CFRX, PRPH, LPTX, and ORMP EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/6/2025Q1 2025EQEquillium-$0.1850N/AN/AN/AN/AN/A5/20/2025Q1 2025PRPHProPhase Labs-$0.18-$0.12+$0.06$0.12$2.45 million$1.43 million5/15/2025Q1 2025ORMPOramed Pharmaceuticals-$0.03-$0.19-$0.16-$0.19N/A$2.00 million5/13/2025Q1 2025LPTXLeap Therapeutics-$0.38-$0.37+$0.01-$0.37N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCFRXContraFectN/AN/AN/AN/AN/AEQEquilliumN/AN/AN/AN/AN/ALPTXLeap TherapeuticsN/AN/AN/AN/AN/AORMPOramed PharmaceuticalsN/AN/AN/AN/AN/APRPHProPhase LabsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCFRXContraFectN/A0.530.53EQEquilliumN/A2.702.70LPTXLeap TherapeuticsN/A2.412.41ORMPOramed PharmaceuticalsN/A23.9423.94PRPHProPhase Labs0.301.030.98Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCFRXContraFect7.85%EQEquillium27.05%LPTXLeap Therapeutics30.46%ORMPOramed Pharmaceuticals12.73%PRPHProPhase Labs9.45%Insider OwnershipCompanyInsider OwnershipCFRXContraFect0.62%EQEquillium31.60%LPTXLeap Therapeutics7.50%ORMPOramed Pharmaceuticals13.70%PRPHProPhase Labs9.60%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCFRXContraFect2310.70 million10.64 millionNot OptionableEQEquillium4035.72 million24.43 millionNot OptionableLPTXLeap Therapeutics4041.44 million38.33 millionOptionableORMPOramed Pharmaceuticals1040.85 million35.25 millionOptionablePRPHProPhase Labs13041.54 million37.55 millionOptionableEQ, CFRX, PRPH, LPTX, and ORMP HeadlinesRecent News About These CompaniesProPhase Labs Regains Nasdaq Compliance with New AppointmentJuly 1, 2025 | tipranks.comProPhase Labs, Inc. Receives Additional 180 Day Extension from Nasdaq to Regain Compliance with Minimum Bid Price Rule - MorningstarJune 27, 2025 | morningstar.comMProPhase Labs Inc. Receives 180-Day Extension from Nasdaq to Regain Bid Price ComplianceJune 26, 2025 | quiverquant.comQProPhase Labs, Inc. Receives Additional 180 Day Extension from Nasdaq to Regain Compliance with Minimum Bid Price RuleJune 26, 2025 | globenewswire.comProphase Labs Appoints Carolina Abenante as DirectorJune 25, 2025 | tipranks.comProPhase Labs Announces Successful Study Demonstrating Performance of BE-Smart™ Test in Detecting Esophageal CancerJune 17, 2025 | globenewswire.comProPhase Labs Announces Formation of Clinical Science Advisory Board to Accelerate Commercialization of BE-SmartTM Esophageal Disease Diagnostic PlatformJune 6, 2025 | globenewswire.comProPhase Labs Announces Financial Results for the Three Months Ended March 31, 2025May 21, 2025 | seekingalpha.comEarnings call transcript: ProPhase Labs beats Q1 2025 EPS forecast, stock risesMay 21, 2025 | investing.comProPhase Labs Inc (PRPH) Q1 2025 Earnings Call Highlights: Strategic Moves and Financial ChallengesMay 21, 2025 | finance.yahoo.comProPhase Labs, Inc. (NASDAQ:PRPH) Q1 2025 Earnings Call TranscriptMay 21, 2025 | msn.comProPhase Labs, Inc. (PRPH) Q1 2025 Earnings Call TranscriptMay 20, 2025 | seekingalpha.comProPhase Labs Q1 2025 Earnings PreviewMay 19, 2025 | msn.comProPhase Labs's Earnings OutlookMay 19, 2025 | benzinga.comProPhase Labs Delays Form 10-Q FilingMay 16, 2025 | tipranks.comProPhase Labs Inc. to Present First Quarter 2025 Financial Results on May 20, 2025May 13, 2025 | globenewswire.comCovid Test Lab Weighs Unusual Debt-Collection Plan: BankruptcyMay 13, 2025 | wsj.comProPhase Labs, Inc. Announces Financial Results for the Year Ended December 31, 2024April 2, 2025 | seekingalpha.comProPhase Labs reports FY24 EPS ($2.61) vs (98c) last yearApril 1, 2025 | markets.businessinsider.comProPhase Labs, Inc. (NASDAQ:PRPH) Q4 2024 Earnings Call TranscriptApril 1, 2025 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesWhy BigBear.ai Could Rally 100% and Catch Palantir SoonBy Gabriel Osorio-Mazilli | June 30, 2025View Why BigBear.ai Could Rally 100% and Catch Palantir Soon3 Defense Leaders Set to Gain From Rising Military SpendBy Chris Markoch | July 5, 2025View 3 Defense Leaders Set to Gain From Rising Military SpendIPO Momentum Returns: 3 Stocks Rising After CoreWeave’s SurgeBy Dan Schmidt | June 20, 2025View IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s SurgeAI Chip Arms Race: 3 Must-Watch Equipment StocksBy Chris Markoch | July 10, 2025View AI Chip Arms Race: 3 Must-Watch Equipment StocksCorrection Equals Opportunity in Domino’s Pizza StockBy Gabriel Osorio-Mazilli | July 6, 2025View Correction Equals Opportunity in Domino’s Pizza StockEQ, CFRX, PRPH, LPTX, and ORMP Company DescriptionsContraFect NASDAQ:CFRXContraFect Corporation, a clinical-stage biotechnology company, discovers and develops therapeutic protein and antibody products for the treatment of life-threatening and drug-resistant infectious diseases in the United States. Its lead program includes Exebacase, a lysin, which is in Phase III clinical trials for the treatment of staphylococcus aureus. The company also developing CF-370, an investigational anti-bacterial therapeutic candidate, which is in Phase 1 clinical trials to treat pseudomonas aeruginosa infections, such as ventilator associated pneumonia, blood stream infections, complicated urinary tract infections, and surgery carry infections. It also developing CF-296, an osteomyelitis and PJI which is in preclinical trailers for the treatment of joint infections. In addition, the company developing Exebacase for the treatment of persistent bacteremia caused by methicillin-resistant staphylococcus aureus in COVID-19 patients. Further, It develops CF-296, an engineered lysin, used for treatment of the invasive infections caused by staphylococcus aureus including biofilm-related infections in prosthetic joints and indwelling devices and osteomyelitis. The company has a license agreement with The Rockefeller University to identify novel lysin therapeutic candidates targeting gram-negative pathogens. ContraFect Corporation was incorporated in 2008 and is headquartered in Yonkers, New York.Equillium NASDAQ:EQ$0.36 +0.01 (+3.10%) As of 03:10 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Equillium, Inc., a clinical-stage biotechnology company, develops and sells products to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need. The company's lead product candidate is itolizumab (EQ001), a first-in-class monoclonal antibody that targets the immune checkpoint receptor CD6, which is in Phase III clinical trials for the treatment of acute graft-versus-host disease; completed Phase I clinical trial for the treatment of ulcerative colitis; and Phase I clinical trial for the treatment of lupus nephritis. It also develops EQ101 completed phase 1/2 for treatment of cutaneous T cell lymphoma and alopecia areata; and EQ302 to treat gastrointestinal indications. In addition, it serves dermatology, gastroenterology, rheumatology, hematology, transplant science, oncology, and pulmonology area. The company was formerly known as Attenuate Biopharmaceuticals, Inc. and changed its name to Equillium, Inc. in May 2017. Equillium, Inc. was incorporated in 2017 and is headquartered in La Jolla, California.Leap Therapeutics NASDAQ:LPTX$0.33 -0.03 (-7.66%) As of 03:03 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Leap Therapeutics, Inc., a biopharmaceutical company, acquires and develops antibody therapies for the treatment of cancer. Its lead product candidates include DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, which is in multiple ongoing clinical trials for treating esophagogastric and gynecologic cancers; and FL-301, a monoclonal antibody that targets cells that express Claudin18.2 on their cell surface and is in phase II clinical trial, as well as two preclinical antibody programs, FL-302 and FL-501. Leap Therapeutics, Inc. has an option and license agreement with NovaRock, Adimab, and BeiGene, Ltd. to develop and commercialize DKN-01 in Asia (excluding Japan), Australia, and New Zealand. The company was formerly known as HealthCare Pharmaceuticals, Inc. and changed its name to Leap Therapeutics, Inc. in November 2015. Leap Therapeutics, Inc. was incorporated in 2011 and is based in Cambridge, Massachusetts.Oramed Pharmaceuticals NASDAQ:ORMP$2.15 +0.03 (+1.42%) As of 03:06 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules for delivery of polypeptides. The company's product portfolio includes ORMD-0801, an oral insulin capsule, which is in phase III clinical trial for the treatment of individuals with diabetes, as well as in phase II clinical trial for the treatment of non-alcoholic steatohepatitis; and ORA-D-013-1 and ORA-D-013-2, which have completed phase II clinical trial for the treatment of type 2 diabetes. It has license agreements with Oravax Medical Inc. to commercialize oral vaccines for COVID-19 and other novel coronaviruses. Oramed Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in New York.ProPhase Labs NASDAQ:PRPH$0.43 0.00 (-0.88%) As of 03:07 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.ProPhase Labs, Inc. develops and commercializes novel drugs, dietary supplements, and compounds in the United States. It operates through two segments: Diagnostic Services and Consumer Products. The company provides a range of TK supplements, including Legendz XL for male sexual health; and Triple Edge XL, an energy and stamina booster. It offers contract manufacturing services, such as product development, pre-commercialization, production, warehousing, and distribution; COVID-19 diagnostic information services to a range of customers, including health plans, third party payers, and government organizations; and respiratory pathogen panel molecular testing services, as well as personal genomics products and services. In addition, the company involved in the research, development, manufacture, distribution, marketing, and sale of over the counter (OTC) consumer healthcare products and dietary supplements; and retail operations. The company was formerly known as The Quigley Corporation. ProPhase Labs, Inc. was founded in 1989 and is headquartered in Garden City, New York. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Super Micro Computer: The Hidden Winner of Soaring Copper Tariffs Nebius Group: Up 385%, Analysts Say It’s Still a Bargain Broadcom Stock: HSBC Sets $400 Target on AI Growth Potential BigBear.ai: Why a 90% Rally Could Be Just the Start Chipotle: Too Spicy for Smart Money to Resist After Stock Split Plug Power’s 20% Surge Signals New Commercial Growth Era Will Oracle's Cloud and AI Deals Propel It to New Highs? Enovix Shares Hit 6-Month High; Long-Term Highs to Follow Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
